Floor and ceiling effects in the EORTC QLQ‐C30 Physical Functioning subscale among patients with advanced or metastatic breast cancer. Issue 4 (11th October 2021)

• Record Type: Journal Article
• Authors: Murugappan, Meena N.; King‐Kallimanis, Bellinda L.; Mangir, Christina; Howie, Lynn; Bhatnagar, Vishal; Beaver, Julia A.; Basch, Ethan M.; Henson, Sydney R.; Kluetz, Paul G.
• Is Part Of: Cancer. Volume 128:Issue 4(2022)
• Page Start: 808
• Page End: 818
• Publication Date: 2021-10-11
• Subjects: breast neoplasms -- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) -- patient‐reported outcome measures -- physical functioning -- quality of life; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33959
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 Physical Functioning subscale is a widely used patient‐reported outcome measure that quantifies cancer patients' physical functioning. Strong floor/ceiling effects can affect a scale's sensitivity to change. The aim of this study was to characterize floor/ceiling effects of the physical functioning domain in patients with advanced/metastatic breast cancer enrolled in commercial clinical trials and a community‐based trial. Methods: The clinical trial cohort comprised patients from 5 registrational trials submitted to the Food and Drug Administration for review (2010‐2017). The community cohort comprised a subgroup of patients from the Alliance Patient Reported Outcomes to Enhance Cancer Treatment (PRO‐TECT) trial. The distribution of patient responses to Physical Functioning items and the summed score were assessed at the baseline and 3‐month follow‐up for both cohorts. Descriptive statistics were used to determine floor/ceiling effects at the item and scale levels. Results: The clinical trial cohort and the community cohort consisted of 2407 and 178 patients, respectively. Twenty‐four percent or more of the respondents reported "not at all" for having trouble/needing help with each Physical Functioning item across both cohorts and measurement time points. Fourteen to twenty percent of the patients scored perfectly (100 of 100) on the Physical Functioning subscale summary measure (where higher scores indicated better physical functioning) across both cohorts and time points. Conclusions: Minor floor effects and notable ceiling effects were found at the item and scale levels of the Physical Functioning subscale, regardless of cohort, and this creates some uncertainty about its ability to detect changes in physical functioning among high‐functioning patients. Investigators may consider adding additional high‐functioning items from the EORTC's item library to more accurately describe the impact of anticancer treatment on patients' physical functioning. Abstract : The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 Physical Functioning subscale is an important tool for measuring cancer patients' physical function in global clinical trials because of its validation across multiple linguistic and cultural contexts. The addition of high‐functioning items from the EORTC item library to the Physical Functioning subscale may allow investigators to more accurately describe the impact of anticancer treatment on patients who are high functioning at the baseline.